Article
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
Blood - 1 Oct 2007
Ottmann Oliver, Dombret Hervé, Martinelli Giovanni, Simonsson Bengt, Guilhot Francois, Larson Richard A, Rege-Cambrin Giovanna, Radich Jerald, Hochhaus Andreas, Apanovitch Anne Marie, Gollerkeri Ashwin, Coutre Steven
Abstract excerpt
Patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL) have a rapid disease course and a poor prognosis. Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.